Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy

Abstract The liver is an essential organ for regulating innate and acquired immunity. We hypothesized that the pre-treatment hepatic function affects the clinical outcome of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). We analyzed 140 patients with NSCLC who received IC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ryosuke Matsukane, Hiroyuki Watanabe, Kojiro Hata, Kimitaka Suetsugu, Toshikazu Tsuji, Nobuaki Egashira, Yoichi Nakanishi, Isamu Okamoto, Ichiro Ieiri
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0a7d6f81e7e64dc4972a52085db8699f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0a7d6f81e7e64dc4972a52085db8699f
record_format	dspace
spelling	oai:doaj.org-article:0a7d6f81e7e64dc4972a52085db8699f2021-12-02T16:50:25ZPrognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy10.1038/s41598-021-94336-92045-2322https://doaj.org/article/0a7d6f81e7e64dc4972a52085db8699f2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94336-9https://doaj.org/toc/2045-2322Abstract The liver is an essential organ for regulating innate and acquired immunity. We hypothesized that the pre-treatment hepatic function affects the clinical outcome of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). We analyzed 140 patients with NSCLC who received ICIs. We investigated the association between pre-treatment liver function, assessed using the albumin–bilirubin (ALBI) grade, and clinical outcomes in univariate, multivariate, and propensity score matching analyses. Patients were divided into four grades according to pre-treatment liver function. Eighty-eight patients had good hepatic reserve (ALBI grade 1 or 2a), whereas 52 patients had poor hepatic reserve (ALBI grade 2b or 3). In the univariate Kaplan–Meier analysis, the ALBI grade 1, 2a group had a significantly prolonged progression-free survival (PFS, 5.3 versus 2.5 months, p = 0.0019) and overall survival (OS, 19.6 vs. 6.2 months, p = 0.0002). These results were consistent, regardless of whether the analysis was performed in patients with a performance status of 0 or 1 at pre-treatment (N = 124) or in those selected using propensity score matching (N = 76). In the multivariate analysis, pre-treatment ALBI grade was an independent prognostic factor for both PFS (hazard ratio [HR] 0.57, 95% confidence interval [95% CI] 0.38–0.86, p = 0.007) and OS (HR 0.45, 95% CI 0.29–0.72, p = 0.001). Our results suggest that pre-treatment hepatic function assessed by ALBI grade could be an essential biomarker for predicting the efficacy of treatment with ICIs in NSCLC.Ryosuke MatsukaneHiroyuki WatanabeKojiro HataKimitaka SuetsuguToshikazu TsujiNobuaki EgashiraYoichi NakanishiIsamu OkamotoIchiro IeiriNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ryosuke Matsukane Hiroyuki Watanabe Kojiro Hata Kimitaka Suetsugu Toshikazu Tsuji Nobuaki Egashira Yoichi Nakanishi Isamu Okamoto Ichiro Ieiri Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
description	Abstract The liver is an essential organ for regulating innate and acquired immunity. We hypothesized that the pre-treatment hepatic function affects the clinical outcome of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). We analyzed 140 patients with NSCLC who received ICIs. We investigated the association between pre-treatment liver function, assessed using the albumin–bilirubin (ALBI) grade, and clinical outcomes in univariate, multivariate, and propensity score matching analyses. Patients were divided into four grades according to pre-treatment liver function. Eighty-eight patients had good hepatic reserve (ALBI grade 1 or 2a), whereas 52 patients had poor hepatic reserve (ALBI grade 2b or 3). In the univariate Kaplan–Meier analysis, the ALBI grade 1, 2a group had a significantly prolonged progression-free survival (PFS, 5.3 versus 2.5 months, p = 0.0019) and overall survival (OS, 19.6 vs. 6.2 months, p = 0.0002). These results were consistent, regardless of whether the analysis was performed in patients with a performance status of 0 or 1 at pre-treatment (N = 124) or in those selected using propensity score matching (N = 76). In the multivariate analysis, pre-treatment ALBI grade was an independent prognostic factor for both PFS (hazard ratio [HR] 0.57, 95% confidence interval [95% CI] 0.38–0.86, p = 0.007) and OS (HR 0.45, 95% CI 0.29–0.72, p = 0.001). Our results suggest that pre-treatment hepatic function assessed by ALBI grade could be an essential biomarker for predicting the efficacy of treatment with ICIs in NSCLC.
format	article
author	Ryosuke Matsukane Hiroyuki Watanabe Kojiro Hata Kimitaka Suetsugu Toshikazu Tsuji Nobuaki Egashira Yoichi Nakanishi Isamu Okamoto Ichiro Ieiri
author_facet	Ryosuke Matsukane Hiroyuki Watanabe Kojiro Hata Kimitaka Suetsugu Toshikazu Tsuji Nobuaki Egashira Yoichi Nakanishi Isamu Okamoto Ichiro Ieiri
author_sort	Ryosuke Matsukane
title	Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
title_short	Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
title_full	Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
title_fullStr	Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
title_full_unstemmed	Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
title_sort	prognostic significance of pre-treatment albi grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0a7d6f81e7e64dc4972a52085db8699f
work_keys_str_mv	AT ryosukematsukane prognosticsignificanceofpretreatmentalbigradeinadvancednonsmallcelllungcancerreceivingimmunecheckpointtherapy AT hiroyukiwatanabe prognosticsignificanceofpretreatmentalbigradeinadvancednonsmallcelllungcancerreceivingimmunecheckpointtherapy AT kojirohata prognosticsignificanceofpretreatmentalbigradeinadvancednonsmallcelllungcancerreceivingimmunecheckpointtherapy AT kimitakasuetsugu prognosticsignificanceofpretreatmentalbigradeinadvancednonsmallcelllungcancerreceivingimmunecheckpointtherapy AT toshikazutsuji prognosticsignificanceofpretreatmentalbigradeinadvancednonsmallcelllungcancerreceivingimmunecheckpointtherapy AT nobuakiegashira prognosticsignificanceofpretreatmentalbigradeinadvancednonsmallcelllungcancerreceivingimmunecheckpointtherapy AT yoichinakanishi prognosticsignificanceofpretreatmentalbigradeinadvancednonsmallcelllungcancerreceivingimmunecheckpointtherapy AT isamuokamoto prognosticsignificanceofpretreatmentalbigradeinadvancednonsmallcelllungcancerreceivingimmunecheckpointtherapy AT ichiroieiri prognosticsignificanceofpretreatmentalbigradeinadvancednonsmallcelllungcancerreceivingimmunecheckpointtherapy
_version_	1718383018838589440

Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy

Ejemplares similares